Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 4;11(17):2758.
doi: 10.3390/cells11172758.

Lung Organoids as Model to Study SARS-CoV-2 Infection

Li Peng  1 , Li Gao  1 , Xinya Wu  1 , Yuxin Fan  1 , Meixiao Liu  1 , Jingjing Chen  1 , Jieqin Song  1 , Jing Kong  1 , Yan Dong  1 , Bingxue Li  1 , Aihua Liu  1   2   3 , Fukai Bao  1   2   3
Affiliations
Review

Lung Organoids as Model to Study SARS-CoV-2 Infection

Li Peng et al. Cells. .

Abstract

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic and has severely affected socio-economic conditions and people's life. The lung is the major target organ infected and (seriously) damaged by SARS-CoV-2, so a comprehensive understanding of the virus and the mechanism of infection are the first choices to overcome COVID-19. Recent studies have demonstrated the enormous value of human organoids as platforms for virological research, making them an ideal tool for researching host-pathogen interactions. In this study, the various existing lung organoids and their identification biomarkers and applications are summarized. At the same time, the seven coronaviruses currently capable of infecting humans are outlined. Finally, a detailed summary of existing studies on SARS-CoV-2 using lung organoids is provided and includes pathogenesis, drug development, and precision treatment. This review highlights the value of lung organoids in studying SARS-CoV-2 infection, bringing hope that research will alleviate COVID-19-associated lung infections.

Keywords: COVID-19; SARS-CoV-2; coronavirus; lung; organoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chronological order of seven coronaviruses capable of infecting humans.
Figure 2
Figure 2
The structure of SARS-CoV-2. (This Figure was created with BioRender software. https://biorender.com/).
Figure 3
Figure 3
Current study of SARS-CoV-2 using lung organoids.(This Figure was created with BioRender software. https://biorender.com/).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Fu L., Wang B., Yuan T., Chen X., Ao Y., Fitzpatrick T., Li P., Zhou Y., Lin Y.-F., Duan Q., et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J. Infect. 2020;80:656–665. doi: 10.1016/j.jinf.2020.03.041. - DOI - PMC - PubMed
    1. WHO . Global Excess Deaths Associated with COVID-19. WHO; Geneva, Switzerland: January 2020–December 2021.
    1. Kannan S.R., Spratt A.N., Cohen A.R., Naqvi S.H., Chand H.S., Quinn T.P., Lorson C.L., Byrareddy S.N., Singh K. Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses. J. Autoimmun. 2021;124:102715. doi: 10.1016/j.jaut.2021.102715. - DOI - PMC - PubMed
    1. Meo S.A., Meo A.S., Al-Jassir F.F., Klonoff D.C. Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur. Rev. Med. Pharm. Sci. 2021;25:8012–8018. - PubMed
    1. Hu K., Guan W.-J., Bi Y., Zhang W., Li L., Zhang B., Liu Q., Song Y., Li X., Duan Z., et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine. 2020;85:153242. doi: 10.1016/j.phymed.2020.153242. - DOI - PMC - PubMed

Publication types